Add Formweb to your mobile device
Search results for:
riTUXimab
riTUXimab
Brand names: Riabni, Rituxan, Ruxience, Truxima
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, INTRAVENOUS | 10 mg/mL; abbs 10 mg/mL; arrx 10 mg/mL; pvvr 10 mg/mL |
Last updated: May. 1, 2024
- Black Box Warning: Fatal infusion reaction; mucocutaneous reactions; progressive multifocal leukoencephalopathy; hep b reactivation
- Therapeutic Interchange: Biosimilar and Reference Products Conversion List for Adults
- Do Not Tube-LALK
Chemotherapy Chart
Medications Approved for Automatic Therapeutic Interchange Dosage Conversion Guidelines
(Note: “Therapeutic Interchange” should be placed in the order comments)
Biosimilar and Reference Products Interchange List for Adults
Medication
Reference Drug or Biosimilar
Formulary Status
Automatic Therapeutic Interchange
Inpatient1
Outpatient
*New Starts/New Authorizations Only *
Ruxience (rituximab-pvvr)
Biosimilar
Formulary
Use Ruxience
Interchange to Truxima unless third party payer requires other rituximab product
Truxima (rituximab-abbs)
Biosimilar
Formulary, restricted to OP
(preferred)
Interchange to Ruxience
Use Truxima unless third party payer requires other rituximab product
Riabni (rituximab-arrx)
Biosimilar
Formulary,
restricted to OP
(not preferred)
Interchange to Ruxience
Interchange to Truxima unless third party payer requires other rituximab product
Rituxan (rituximab)
Reference
Rituxan is the only rituximab product FDA approved for use in pemphigus vulgaris.